JPS5935363B2 - Composition of skin emulsion - Google Patents
Composition of skin emulsionInfo
- Publication number
- JPS5935363B2 JPS5935363B2 JP3732577A JP3732577A JPS5935363B2 JP S5935363 B2 JPS5935363 B2 JP S5935363B2 JP 3732577 A JP3732577 A JP 3732577A JP 3732577 A JP3732577 A JP 3732577A JP S5935363 B2 JPS5935363 B2 JP S5935363B2
- Authority
- JP
- Japan
- Prior art keywords
- weight
- group
- skin
- composition
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000839 emulsion Substances 0.000 title claims description 32
- 239000000203 mixture Substances 0.000 title claims description 28
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 26
- -1 2,4-dichlorobenzyl group Chemical group 0.000 claims description 16
- 235000012000 cholesterol Nutrition 0.000 claims description 13
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 9
- 239000010696 ester oil Substances 0.000 claims description 9
- 239000000194 fatty acid Substances 0.000 claims description 9
- 229930195729 fatty acid Natural products 0.000 claims description 9
- 150000004665 fatty acids Chemical class 0.000 claims description 9
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 3
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000006178 methyl benzyl group Chemical group 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 125000004803 chlorobenzyl group Chemical group 0.000 claims 1
- 235000002639 sodium chloride Nutrition 0.000 description 22
- 230000000052 comparative effect Effects 0.000 description 9
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 230000002378 acidificating effect Effects 0.000 description 7
- 230000007794 irritation Effects 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 206010015150 Erythema Diseases 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 6
- JBIROUFYLSSYDX-UHFFFAOYSA-M benzododecinium chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 JBIROUFYLSSYDX-UHFFFAOYSA-M 0.000 description 6
- 231100000321 erythema Toxicity 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- GLYJVQDYLFAUFC-UHFFFAOYSA-N butyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCCCC GLYJVQDYLFAUFC-UHFFFAOYSA-N 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 235000019606 astringent taste Nutrition 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- GOQYKNQRPGWPLP-UHFFFAOYSA-N heptadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 3
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- CMBYOWLFQAFZCP-UHFFFAOYSA-N Hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- PXFDQFDPXWHEEP-UHFFFAOYSA-M benzyl-dimethyl-octylazanium;chloride Chemical compound [Cl-].CCCCCCCC[N+](C)(C)CC1=CC=CC=C1 PXFDQFDPXWHEEP-UHFFFAOYSA-M 0.000 description 2
- DHAZIUXMHRHVMP-UHFFFAOYSA-N butyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCCCC DHAZIUXMHRHVMP-UHFFFAOYSA-N 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- RQIKFACUZHNEDV-UHFFFAOYSA-N dihexadecyl hexanedioate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCC(=O)OCCCCCCCCCCCCCCCC RQIKFACUZHNEDV-UHFFFAOYSA-N 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 238000005562 fading Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- FIENEGBWDWHXGG-YPKPFQOOSA-N hexyl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCCCCC FIENEGBWDWHXGG-YPKPFQOOSA-N 0.000 description 2
- IOVYZELOJXWQKD-UHFFFAOYSA-N hexyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCCCCCC IOVYZELOJXWQKD-UHFFFAOYSA-N 0.000 description 2
- 229940100463 hexyl laurate Drugs 0.000 description 2
- SMWDEDPRQFUXNH-UHFFFAOYSA-N hexyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCC SMWDEDPRQFUXNH-UHFFFAOYSA-N 0.000 description 2
- JIFCVUWJQMDNTN-UHFFFAOYSA-N hexyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCCCCCC JIFCVUWJQMDNTN-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- WIBFFTLQMKKBLZ-SEYXRHQNSA-N n-butyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCCC WIBFFTLQMKKBLZ-SEYXRHQNSA-N 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- REIUXOLGHVXAEO-UHFFFAOYSA-N pentadecan-1-ol Chemical compound CCCCCCCCCCCCCCCO REIUXOLGHVXAEO-UHFFFAOYSA-N 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- GGHPAKFFUZUEKL-UHFFFAOYSA-M sodium;hexadecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCOS([O-])(=O)=O GGHPAKFFUZUEKL-UHFFFAOYSA-M 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- PCOYBSIUQQLBEB-UHFFFAOYSA-M (2,4-dichlorophenyl)methyl-dodecyl-dimethylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=C(Cl)C=C1Cl PCOYBSIUQQLBEB-UHFFFAOYSA-M 0.000 description 1
- YWMSPYAVKFABPD-UHFFFAOYSA-M (3,4-dichlorophenyl)methyl-dodecyl-dimethylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=C(Cl)C(Cl)=C1 YWMSPYAVKFABPD-UHFFFAOYSA-M 0.000 description 1
- UZIKEAMJPPJPPH-UHFFFAOYSA-N (4-chlorophenyl)methyl-dimethylazanium chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=C(Cl)C=C1 UZIKEAMJPPJPPH-UHFFFAOYSA-N 0.000 description 1
- SMIXZZMSWYOQPW-UHFFFAOYSA-N (4-nitrophenyl)methylazanium;chloride Chemical compound [Cl-].[NH3+]CC1=CC=C([N+]([O-])=O)C=C1 SMIXZZMSWYOQPW-UHFFFAOYSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- ZDFDJKNMVBIUTI-UHFFFAOYSA-N 1-(2-bromopropan-2-yl)-2-dodecylbenzene Chemical compound CCCCCCCCCCCCC1=CC=CC=C1C(C)(C)Br ZDFDJKNMVBIUTI-UHFFFAOYSA-N 0.000 description 1
- HMDFOXQIYPYCRX-UHFFFAOYSA-N 1-(2-chloropropan-2-yl)-2-dodecylbenzene Chemical compound CCCCCCCCCCCCC1=CC=CC=C1C(C)(C)Cl HMDFOXQIYPYCRX-UHFFFAOYSA-N 0.000 description 1
- UMESNHVJZFCGBV-UHFFFAOYSA-N 2-methyl-4-[(2-methylphenyl)methylidene]-1,3-oxazol-5-one Chemical compound O=C1OC(C)=NC1=CC1=CC=CC=C1C UMESNHVJZFCGBV-UHFFFAOYSA-N 0.000 description 1
- 125000006512 3,4-dichlorobenzyl group Chemical group [H]C1=C(Cl)C(Cl)=C([H])C(=C1[H])C([H])([H])* 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- VBIIFPGSPJYLRR-UHFFFAOYSA-M Stearyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)C VBIIFPGSPJYLRR-UHFFFAOYSA-M 0.000 description 1
- FWGYKDKINNGPSG-UHFFFAOYSA-N [Cl-].Cl[NH+](CC1=CC=CC=C1)Cl Chemical compound [Cl-].Cl[NH+](CC1=CC=CC=C1)Cl FWGYKDKINNGPSG-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- CHQDFPKUWSDOEC-UHFFFAOYSA-M benzyl-(2-ethylhexyl)-dimethylazanium;chloride Chemical compound [Cl-].CCCCC(CC)C[N+](C)(C)CC1=CC=CC=C1 CHQDFPKUWSDOEC-UHFFFAOYSA-M 0.000 description 1
- RWUKNUAHIRIZJG-AFEZEDKISA-M benzyl-dimethyl-[(z)-octadec-9-enyl]azanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC[N+](C)(C)CC1=CC=CC=C1 RWUKNUAHIRIZJG-AFEZEDKISA-M 0.000 description 1
- SXPWTBGAZSPLHA-UHFFFAOYSA-M cetalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SXPWTBGAZSPLHA-UHFFFAOYSA-M 0.000 description 1
- 229960000228 cetalkonium chloride Drugs 0.000 description 1
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 150000001804 chlorine Chemical group 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- HXWGXXDEYMNGCT-UHFFFAOYSA-M decyl(trimethyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCC[N+](C)(C)C HXWGXXDEYMNGCT-UHFFFAOYSA-M 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- DDXLVDQZPFLQMZ-UHFFFAOYSA-M dodecyl(trimethyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)C DDXLVDQZPFLQMZ-UHFFFAOYSA-M 0.000 description 1
- FETGTBGFTLMQBL-UHFFFAOYSA-M dodecyl-dimethyl-[(4-nitrophenyl)methyl]azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=C([N+]([O-])=O)C=C1 FETGTBGFTLMQBL-UHFFFAOYSA-M 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 229940080236 sodium cetyl sulfate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- CFSCETSZQVECLC-UHFFFAOYSA-M trimethyl(1-phenyltridecyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCC([N+](C)(C)C)C1=CC=CC=C1 CFSCETSZQVECLC-UHFFFAOYSA-M 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Cosmetics (AREA)
Description
【発明の詳細な説明】
本発明は、肌を刺激することな(肌に適度の良好な収斂
性、しっとり感、なめらかさ、および殺菌効果を与え、
しかも保存安定性の優れた非粘性の酸性スキン乳液の組
成物に関する。DETAILED DESCRIPTION OF THE INVENTION The present invention provides a skin care product that does not irritate the skin (gives the skin moderate and good astringency, moisturizing, smoothness, and bactericidal effect,
Moreover, it relates to a non-viscous acidic skin emulsion composition with excellent storage stability.
従来、高級アルキル硫酸エステル塩を含するスキン乳液
は、皮膚に刺激を与え、コレステロール等を含有する場
合でも酸性側(PH4〜6.0)で加水分解を惹起して
乳化安定性が低下し易い欠点があった。Conventionally, skin emulsions containing higher alkyl sulfate ester salts irritate the skin, and even if they contain cholesterol, etc., they tend to cause hydrolysis on the acidic side (PH 4 to 6.0), resulting in a decrease in emulsion stability. There were drawbacks.
また直鎖構造の脂肪酸エステル油と高級アルコール硫酸
エステル塩を含有するスキン乳液は、それらの加水分解
が起り易(、かつ乳化安定性と保存安定性が著しく低下
し易い欠点があった。Furthermore, skin emulsions containing linear fatty acid ester oils and higher alcohol sulfate ester salts have the disadvantage that they are easily hydrolyzed (and their emulsion stability and storage stability tend to be significantly reduced).
本発明者は、高級アルコール硫酸エステル塩とコレステ
ロールとを含有するスキン乳化液の欠点を改良せんとし
て、鋭意研究した結果、後記一般式(1)で表わされる
特定の第4級アンモニウム塩と、一般式(2)の高級ア
ルコール硫酸エステル塩とコレステロール食塩と直鎖構
造の脂肪酸エステル油と水を混合したスキン乳化液は、
酸性側でも高級アルコール硫酸エステル塩及び直鎖構造
の脂肪酸エステル油の加水分解反応が未然に防止され、
長期保存時における乳化安定性が著しく向上、改良され
、しかも使用に際しては、皮膚(肌)に刺激を与えるこ
となく、しっとり感、なめらかさ、収斂性および殺菌効
果をも施与発現し得ることを見出し、本発明を完成した
。As a result of intensive research in an attempt to improve the drawbacks of skin emulsions containing higher alcohol sulfate ester salts and cholesterol, the present inventors discovered that a specific quaternary ammonium salt represented by general formula (1) below and The skin emulsion is a mixture of the higher alcohol sulfate ester salt of formula (2), cholesterol salt, linear fatty acid ester oil, and water.
Even on the acidic side, the hydrolysis reaction of higher alcohol sulfate ester salts and linear fatty acid ester oils is prevented,
The emulsion stability during long-term storage has been significantly improved and improved, and when used, it has a moist feeling, smoothness, astringency, and bactericidal effect without irritating the skin. The present invention has been completed.
本発明の目的は、乳化安定性、保存安定性に優れ、使用
時には肌に刺激を与えることなく、適度の良好なしっと
り感、なめらかさ、収斂性、殺菌効果を与えるスキン乳
液の組成物を提供することである。The purpose of the present invention is to provide a skin emulsion composition that has excellent emulsion stability and storage stability, and provides a moderately good moist feeling, smoothness, astringency, and bactericidal effect without irritating the skin during use. It is to be.
本発明は、下記一般式(1)(上記式中で、Rは炭素数
6〜17個のアルキル基またはフルケニル基、R′はベ
ンジル基、4−ニトロベンジル基、3・4−ジクロロベ
ンジル基、4−クロロベンジル基、2・4−ジクロロヘ
ンシル基、メチルベンジル基またはメチル基である)で
表わされる第4級アンモニウム塩が0.025〜0.0
5重量%(重量%は、組成物重量基準8以下同じ)、コ
レステロールが0.1〜2,0重量%、下記一般式(2
)
%式%(2)
(上記式中で、Rは炭素数11〜18のアルキル基また
はアルケニル基、Aはナトリウム、カリウムまたはNH
4である)
で表わされる高級アルコール硫酸エステル塩が0.1〜
2重量%、直鎖構造の脂肪酸エステル油が1〜20重量
%、食塩が0.05〜0.5重量%及び水が75〜98
重量%配合されていることを特徴とする、スキン乳液の
組成物である。The present invention is based on the following general formula (1) (in the above formula, R is an alkyl group having 6 to 17 carbon atoms or a fluorenyl group, and R' is a benzyl group, 4-nitrobenzyl group, 3,4-dichlorobenzyl group). , 4-chlorobenzyl group, 2,4-dichlorohensyl group, methylbenzyl group or methyl group) is 0.025 to 0.0
5% by weight (weight% is the same as 8 or less based on the weight of the composition), cholesterol is 0.1 to 2.0% by weight, and the following general formula (2
) % formula % (2) (In the above formula, R is an alkyl group or alkenyl group having 11 to 18 carbon atoms, A is sodium, potassium or NH
The higher alcohol sulfate ester salt represented by 4) is 0.1 to
2% by weight, linear fatty acid ester oil 1-20% by weight, salt 0.05-0.5% by weight, and water 75-98% by weight.
This is a skin emulsion composition, characterized in that it contains % by weight.
本発明に使用する特定の第4級アンモニウム塩は、前記
一般式(1)で表わされるものであって、一種又は二種
以上組合せて使用する。The specific quaternary ammonium salts used in the present invention are represented by the general formula (1), and may be used singly or in combination of two or more.
その配合量(以下、含有量と記載する)は処方成分の全
量重量(以下、組成物重量と記載する)に対して0.0
25〜0.05重量%、好ましくは0.03〜0.04
重量%である。The blended amount (hereinafter referred to as content) is 0.0 based on the total weight of the prescription ingredients (hereinafter referred to as composition weight).
25-0.05% by weight, preferably 0.03-0.04
Weight%.
0.025重量%よりも少ないと、組成物の乳化安定性
、保存安定性が低下する傾向があり、0.05重量%よ
りも多(なると強刺性が強くなる傾向がある。If it is less than 0.025% by weight, the emulsion stability and storage stability of the composition will tend to decrease, and if it is more than 0.05% by weight, it will tend to have strong pungent properties.
前記一般式(1)で示される第4級アンモニウム塩の中
で特に好ましいものは、ラウリルジメチルベンジルアン
モニウムクロライド、オクチルジメチルベンジルアンモ
ニウムクロライド、ラウリルジメチル4−ニトロベンジ
ルアンモニウムクロライド、ラウリルジメチル3・4−
ジクロロベンジルアンモニウムクロライド、ラウリルジ
メチルイソ−ジクロロベンジルクロライド、ラウリルト
リメチルアンモニウムクロライド等である。Among the quaternary ammonium salts represented by the general formula (1), particularly preferred are lauryldimethylbenzylammonium chloride, octyldimethylbenzylammonium chloride, lauryldimethyl 4-nitrobenzylammonium chloride, lauryldimethyl 3,4-
These include dichlorobenzylammonium chloride, lauryldimethyliso-dichlorobenzylchloride, lauryltrimethylammonium chloride, and the like.
コレステロールの含有量は、組成物重量に対して0.1
〜2重量%、好ましくは0.3〜1.5重量%である。The content of cholesterol is 0.1 based on the weight of the composition.
-2% by weight, preferably 0.3-1.5% by weight.
0.1重量%よりも少な(なると乳化安定性、保存安定
性が低下し、2重量%よりも多(なると安定な非粘性の
乳液が生成し難くなる傾向がある。If the amount is less than 0.1% by weight, emulsion stability and storage stability will decrease, and if it is more than 2% by weight, it will be difficult to produce a stable non-viscous emulsion.
本発明に使用する高級アルコール硫酸エステル塩は前記
一般式(2)で表わされるもので、ウンテジシルアルコ
ール硫酸エステル、ラウリルアルコール硫酸エステル、
トリテシルアルコール硫酸エステル、ミリスチルアルコ
ール硫酸エステル、ペンタデシルアルコール硫酸エステ
ル、セチルアルコール硫酸エステル、ヘプタデシルアル
コール硫酸エステル、オレイルアルコール硫酸エステル
、ステアリルアルコール硫酸エステルのナトリウム塩、
カリウム塩、またはアンモニウム塩等が好ましいものと
して例示される。The higher alcohol sulfate ester salts used in the present invention are those represented by the general formula (2), and include untedisyl alcohol sulfate, lauryl alcohol sulfate,
Sodium salt of tritesyl alcohol sulfate, myristyl alcohol sulfate, pentadecyl alcohol sulfate, cetyl alcohol sulfate, heptadecyl alcohol sulfate, oleyl alcohol sulfate, stearyl alcohol sulfate,
Preferred examples include potassium salts and ammonium salts.
高級アルコール硫酸エステル塩は一種または二種以上組
合せて使用することができ、その使用量(含有量)は、
組成物重量に対してo、i〜2重量%、好ましくは、0
.3〜1.5重量%である。Higher alcohol sulfate ester salts can be used singly or in combination of two or more, and the amount used (content) is as follows:
o, i to 2% by weight relative to the weight of the composition, preferably 0
.. It is 3 to 1.5% by weight.
0.1重量%よりも少な(なると乳化安定性、保存安定
性が低下し、2重量%よりも多くなると非粘性の乳液が
生成し難(なる。If the amount is less than 0.1% by weight, emulsion stability and storage stability will decrease, and if it is more than 2% by weight, it will be difficult to form a non-viscous emulsion.
食塩の含有量は、組成物重量に対して0.05〜0.5
重量%、好ましくは0.1〜0.3重量%である。The content of salt is 0.05 to 0.5 based on the weight of the composition.
% by weight, preferably 0.1-0.3% by weight.
0.05重量%より少なくなると、高級アルコール硫酸
エステルや該エステル油の安定性や保存安定性が低下し
、0.5重量%よりも多くなると違和感を強(感じ、保
存安定性が低下する傾向がある。If it is less than 0.05% by weight, the stability and storage stability of the higher alcohol sulfate ester and the ester oil will decrease, and if it is more than 0.5% by weight, there will be a strong feeling of discomfort and the storage stability will tend to decrease. There is.
直鎖構造の脂肪酸エステル油の含有量は組成物重量に対
して、1〜20重量%、好ましくは3〜15重量%であ
る。The content of the linear fatty acid ester oil is 1 to 20% by weight, preferably 3 to 15% by weight, based on the weight of the composition.
1重量%よりも少な(なるとスキン乳液としての機能が
なく、乳化安定性、保存安定性が低下する傾向があり、
20重量%よりも多くなると粘性が出て来て、酸性の非
粘性物が得難くなる。If it is less than 1% by weight, it will not function as a skin emulsion and the emulsion stability and storage stability will tend to decrease.
If it exceeds 20% by weight, viscosity will appear and it will be difficult to obtain an acidic, non-viscous material.
本発明に使用する直鎖構造の脂肪酸エステル油とは、直
鎖状の脂肪酸と直鎖状の一価アルコールとのエステル化
油であって、例えば、ブチルステアレート、ヘキシルラ
ウレート、ブチルパルミテート、ブチルミリステート、
ヘキシルステアレート、ヘキシルパルミテート、ヘキシ
ルミリステート、ブチルオレート、ヘキシルオレート、
ヘキサデシルアジペート、あるいはそれらの組合せが好
ましいものとして例示される。The linear fatty acid ester oil used in the present invention is an esterified oil of a linear fatty acid and a linear monohydric alcohol, such as butyl stearate, hexyl laurate, butyl palmitate. , butyl myristate,
hexyl stearate, hexyl palmitate, hexyl myristate, butyl oleate, hexyl oleate,
Preferred examples include hexadecyl adipate and a combination thereof.
水の含有量は、組成物重量に対して75〜98重量%で
ある。The water content is between 75 and 98% by weight, based on the weight of the composition.
好ましくは81.5〜96.0重量%である。Preferably it is 81.5 to 96.0% by weight.
75重量%より少な(なると冬期のような低温下で安定
性が低下し易(、また95重量%よりも多(なると、夏
期のような高温下では安定性が低下し易い傾向がある。If it is less than 75% by weight, stability tends to decrease under low temperatures such as in winter (and if it exceeds 95% by weight, stability tends to decrease under high temperatures such as in summer).
また本発明はスキン乳液組成物に、PH調整剤として水
易溶性の有機酸単独または有機酸塩との混合物からなる
公知のPH緩衝剤を添加含有して、PHを調節すること
ができる。Further, in the present invention, the skin emulsion composition may contain, as a PH adjuster, a known PH buffering agent consisting of a water-soluble organic acid alone or a mixture with an organic acid salt to adjust the PH.
本発明組成物は、所要量の直鎖構造の脂肪酸エステル化
油とコレステロールとを加温した均一混合液に、食塩と
水と第4級アンモニウム塩と高級アルコール硫酸エステ
ル塩とからなる溶液を添加し、攪拌下に混合乳化分散す
ることによって製造される。In the composition of the present invention, a solution consisting of common salt, water, a quaternary ammonium salt, and a higher alcohol sulfate ester salt is added to a homogeneous mixture obtained by heating the required amount of linear fatty acid esterified oil and cholesterol. It is manufactured by mixing and emulsifying and dispersing it while stirring.
本発明のスキン乳液の組成物は、酸性で非粘調性の液状
物であって、共存する食塩及び前記第4級アンモニウム
塩は安定剤としても作用し、長期保存安定性に優れ、2
年間保存しても極めて安定で分離や加水分解を生起する
ことがない。The skin emulsion composition of the present invention is an acidic, non-viscous liquid, and the coexisting common salt and the quaternary ammonium salt also act as stabilizers and have excellent long-term storage stability.
It is extremely stable and does not undergo separation or hydrolysis even when stored for years.
しかし後述の比較例の如く、食塩が共存しても前記一般
式に示される第4級アンモニウム塩の塩素原子が臭素原
子で置換されるような本発明以外のものでは高級アルコ
ール硫酸エステル塩や該エステル油の加水分解を防止す
ることができない等、食塩及び前記特定構造の第4級ア
ンモニウム塩の共存作用効果の特異性は著しい。However, as shown in the comparative examples described below, even if common salt is present, the quaternary ammonium salt shown in the above general formula has a chlorine atom substituted with a bromine atom. The coexistence effect of common salt and the quaternary ammonium salt having the above-mentioned specific structure is very specific, such as not being able to prevent the hydrolysis of ester oil.
以下、本発明の詳細な説明する。The present invention will be explained in detail below.
尚、部とは重量部を、%とは重量%を意味する。Note that "part" means part by weight, and "%" means % by weight.
実施例 1
(1)本発明のスキン乳液の組成
■、ブチルステアレート(純分) 5部2、コレ
ステロール(純分) 05部3、ラウリルジメ
チルベンジル
アンモニウムクロライド
(純分) 0.05部4食塩
(精製塩)0.1部
5、セチル硫酸ソーダ(純分)0.7部
6、香料色素 適 量7、水
93.3部計100部
(2)スキン乳液の組成物の製造
流動パラフィンにコレステロールを加温溶解せしめ(A
)を調製した。Example 1 (1) Composition of the skin emulsion of the present invention ■, butyl stearate (pure) 5 parts 2, cholesterol (pure) 05 parts 3, lauryldimethylbenzylammonium chloride (pure) 0.05 parts 4 common salt (Purified salt) 0.1 part 5, Sodium cetyl sulfate (purity) 0.7 part 6, Flavor pigment appropriate amount 7, Water
93. 3 parts total 100 parts (2) Production of skin emulsion composition Dissolve cholesterol in liquid paraffin by heating (A
) was prepared.
次に食塩とラウリルジメチルベンジルアンモニウムクロ
ライドを添加、加熱しセチルアルコール硫酸エステルソ
ーダ塩を加え均一混合溶液(B )を調製した。Next, common salt and lauryldimethylbenzylammonium chloride were added, heated, and cetyl alcohol sulfate ester soda salt was added to prepare a homogeneous mixed solution (B).
前記混合溶液の(A)にCB)を攪拌下に加え、混合し
て後香料、色素を加え攪拌しながら室温まで冷却して本
発明のスキン乳液の組成物を得た。CB) was added to (A) of the mixed solution with stirring, and after mixing, perfume and pigment were added and cooled to room temperature while stirring to obtain a skin emulsion composition of the present invention.
(3)比較例のスキン乳液の組成物
■ 比較例1として、ラウリルジメチルベンジルクロラ
イドの代りにラウリルジメチルベンジルブロマイドを使
用する他は、本発明と同様に行なった。(3) Comparative Example Skin Emulsion Composition ■ Comparative Example 1 was carried out in the same manner as in the present invention except that lauryl dimethyl benzyl bromide was used instead of lauryl dimethyl benzyl chloride.
■ 比較例2として、コレステロールの代りにフィトス
テロールを使用する他は、本発明と同様に行なった。(2) Comparative Example 2 was carried out in the same manner as in the present invention except that phytosterol was used instead of cholesterol.
■ 比較例3として、セチル硫酸ソーダの代りにステア
リン酸トリエタノールアンモニウム塩を使用する他は、
本発明と同様に行なった。■ As Comparative Example 3, except that stearic acid triethanolammonium salt was used instead of cetyl sodium sulfate,
It was carried out in the same manner as in the present invention.
■ 比較例4として、ラウリルジメチルベンジルアンモ
ニウムクロライドのみを使用しない他は、本発明と同様
に行なった。(2) Comparative Example 4 was carried out in the same manner as in the present invention except that lauryldimethylbenzylammonium chloride was not used.
■ 比較例5として、食塩のみを使用しない他は、本発
明と同様に行なった。(2) Comparative Example 5 was carried out in the same manner as in the present invention except that only common salt was not used.
(4)次に本発明例と比較例の組成物の保存安定性、外
観、褪色テスト、官能試験(肌なじみ、肌のなめらかさ
、しっとり感、刺激感)についてしらべた。(4) Next, the storage stability, appearance, fading test, and sensory test (skin compatibility, skin smoothness, moist feeling, and irritation) of the compositions of the present invention examples and comparative examples were examined.
それ等の結果を第1表に示した。尚、第1表中の外観は
肉眼観察、保存安定性は一10℃で2週間、45℃で2
週間のサイクルで6ケ月間恒温室に保存した時の状態が
均一な乳液の場合は安定、不均一な乳液の場合は不安定
とした。The results are shown in Table 1. In addition, the appearance in Table 1 is observed with the naked eye, and the storage stability is measured at -10℃ for 2 weeks and at 45℃ for 2 weeks.
A milky lotion with a uniform state when stored in a constant temperature room for 6 months on a weekly cycle was considered stable, and a non-uniform milky lotion was considered unstable.
官能試験は女性20名をパネルとして行い、数字は刺激
感以外は良いと答えた人数である。The sensory test was conducted with a panel of 20 women, and the numbers are the number of people who answered that the product was good except for the irritation.
褪色テストはフェトメーターテスト4時間かけた後の色
を肉眼判定で行なった。The fading test was conducted by visual judgment of the color after 4 hours of fetometer testing.
この結果から明らかなように、本発明実施例1の組成物
は、比較例の該組成物に比較して均一乳化性、保存安定
性、官能性が著しく優れている。As is clear from the results, the composition of Example 1 of the present invention is significantly superior in uniform emulsifying property, storage stability, and functionality compared to the composition of Comparative Example.
そして本発明の構成成分の代りに、類縁性成分を混用し
ても良好な非粘性の酸性乳液の組成物が得られない。Even if similar components are used in place of the constituent components of the present invention, a good non-viscous acidic emulsion composition cannot be obtained.
※※実施例
2
ラウリルジメチルベンジルアンモニウムクロライドの含
有量を第2表の如(変化させる他は、実施例1の本発明
と同様に行なった。※※Example
2 The same procedure as in Example 1 of the present invention was carried out except that the content of lauryldimethylbenzylammonium chloride was changed as shown in Table 2.
その結果を第2表に示した。The results are shown in Table 2.
この結果から明らかなように、前記特定の第4級アンモ
ニウム塩の含有量は0.025〜0.05%、好ましく
は0.03〜0.04%である。As is clear from this result, the content of the specific quaternary ammonium salt is 0.025 to 0.05%, preferably 0.03 to 0.04%.
動物皮膚刺激試験
1)raizeの方法に準じ、被検試料0.5 rul
を塗布したパッチ片を背後の毛を刈り取った白色家兎(
3羽を使用)の皮膚に貼布する。Animal skin irritation test 1) According to the method of RAISE, test sample 0.5 rul
A patch piece coated with a white rabbit with its back fur shaved (
Apply to the skin of 3 birds (using 3 birds).
家兎をゴム衣で覆い、動かぬよう動物ホールグー中に固
定する。Cover the rabbit with rubber clothing and secure it in an animal cage to prevent movement.
24時間後にパッチ片を取り除き、下記の判定基準に従
い、反応の度合を記録する。After 24 hours, the patch pieces are removed and the degree of reaction is recorded according to the criteria below.
又、72時間後にも判定を行い、24時間後と72時間
後のスコアー平均値を算出し、刺激スコアーとする。Further, the determination is also made after 72 hours, and the average score after 24 hours and after 72 hours is calculated and used as the irritation score.
判定
(1) 紅斑及び皮形成
紅斑なし 0
極めて軽微な紅斑 1
確認できる紅斑 2
中程度〜激しい紅斑 3
激しい紅斑と軽い皮形成 4
(2)浮腫の形成
浮腫なし 0
極めて軽微な浮腫 1
軽微な浮腫 2
中程度の浮腫 3 ン4 激
しい浮腫 4評価
算出したスコアー値により、刺激の度合は次の様に評価
される
0〜2 僅かな刺激又は殆んど刺激なし2以上
〜5以上 中程度の刺激
5以上 強い刺激
実施例 3
コレステロールの含有量を第3表の如(変化させる他は
、実施例10本発明と同様に行なった。Judgment (1) No erythema or skin formation erythema 0 Very slight erythema 1 Visible erythema 2 Moderate to severe erythema 3 Severe erythema and slight skin formation 4 (2) Formation of edema No edema 0 Very slight edema 1 Slight edema 2 Moderate edema 3 N4 Severe edema 4 Evaluation Based on the calculated score value, the degree of irritation is evaluated as follows: 0 to 2 Slight irritation or almost no irritation 2 or more to 5 or more Moderate irritation 5 or more Strong stimulation Example 3 The same procedure as in Example 10 of the present invention was carried out except that the cholesterol content was changed as shown in Table 3.
その結果を第3表に示した。The results are shown in Table 3.
この結果から明らかなようにコレステロールの含有量が
0.1%より少な(なると、また、2%より多くなると
安定度が悪(なり、0.3〜1.5%の範囲内で非粘性
の酸性乳液が得られる。As is clear from this result, if the cholesterol content is less than 0.1% (or more than 2%), the stability will be poor (if the cholesterol content is less than 0.1%), the stability will be poor (if the cholesterol content is more than 2%) An acidic emulsion is obtained.
」*実施例 4
食塩の含有量を第4表の如(変化させる他は、本発明の
実施例1と同様に行なった。*Example 4 The same procedure as Example 1 of the present invention was conducted except that the salt content was changed as shown in Table 4.
その結果を第4表に示した。The results are shown in Table 4.
この結果から明らかなように食塩の含有量が0.05%
より少な(、また0、5%より多くなると均一な乳化が
得られない。As is clear from this result, the salt content is 0.05%.
If the amount is less (or more than 0.5%), uniform emulsification cannot be obtained.
実施例 5
ラウリルジメチルベンジルアンモニウムクロライドの代
りに、第4級アンモニウム塩として、ステアリルトリメ
チルアンモニウムクロライド(A1)、セチルトリメチ
ルアンモニウムクロライド(A2)、n−オクチルトリ
メチルアンモニウムクロライド(A3)、カプリルトリ
メチルアンモニウムクロライド(A4)、カプリルジメ
チルベンジルアンモニウムクロライド(A;、5)、オ
レイルジメチルベンジルアンモニウムクロライド(A6
)、2−エチルへキシルジメチルベンジルアンモニウム
クロライド(A7)、オクチルジメチルベンジルアンモ
ニウムクロライド(A8)、セチルジメチルベンジルア
ンモニウムクロライド(A9)、7ウリルジメチル4−
ニトロベンジルアンモニウムクロライド(AIO)、ラ
ウリルジメチル2・4−ジクロロベンジルアンモニウム
クロライド(A11.)、ラウリルジメチルメチルベン
ジルアンモニウムクロライド(A、 12 )、ラウリ
ルジメチル3・4−ジクロロベンジルアンモニウムクロ
ライド(A13)、ラウリルジメチル4−クロロベンジ
ルアンモニウムクロライI’(Al 4 )’を使用す
る他は、実施例10本発明と同様に行なった。Example 5 Instead of lauryldimethylbenzylammonium chloride, stearyltrimethylammonium chloride (A1), cetyltrimethylammonium chloride (A2), n-octyltrimethylammonium chloride (A3), capryltrimethylammonium chloride ( A4), capryldimethylbenzylammonium chloride (A;, 5), oleyldimethylbenzylammonium chloride (A6
), 2-ethylhexyldimethylbenzylammonium chloride (A7), octyldimethylbenzylammonium chloride (A8), cetyldimethylbenzylammonium chloride (A9), 7uryldimethyl 4-
Nitrobenzylammonium chloride (AIO), lauryldimethyl 2,4-dichlorobenzylammonium chloride (A11.), lauryldimethylmethylbenzylammonium chloride (A, 12), lauryldimethyl 3,4-dichlorobenzylammonium chloride (A13), lauryl The same procedure as in Example 10 of the present invention was conducted except that dimethyl 4-chlorobenzylammonium chloride I'(Al 4 )' was used.
その結果を第5表に示した。実施例 6
ブチルステアレートの代りに、ヘキシルラウレート、ブ
チルパルミテート、ブチルミリステート、ヘキシルステ
アレート、ヘキシルパルミテート、ヘキシルミリステー
ト、ブチルオレート、ヘキシルオレート、ヘキサデシル
アジペートの夫々を使用する他は、実施例10本発明と
同様に行ない各スキン乳液を製造した。The results are shown in Table 5. Example 6 Instead of butyl stearate, each of hexyl laurate, butyl palmitate, butyl myristate, hexyl stearate, hexyl palmitate, hexyl myristate, butyl oleate, hexyl oleate, and hexadecyl adipate was used. , Example 10 Each skin emulsion was produced in the same manner as in the present invention.
得られた各スキン乳液は、実施例10本発明のスキン乳
液と同様に均一な乳化液を形成しており、PHは4.6
で6力月保存したが何等乳化状態に異状が見られず極め
て安定であった。Each of the obtained skin emulsions formed a uniform emulsion similar to the skin emulsion of the present invention in Example 10, and the pH was 4.6.
The emulsified product was stored for 6 months, but no abnormalities were observed in the emulsified state and it was extremely stable.
Claims (1)
はアルケニル基、R′はベンジル基、4−ニトロベンジ
ル基、3・4−)クロロベンジル基、4−クロロベンジ
ル基、2・4−ジクロロベンジル基、メチルベンジル基
またはメチル基である)で表わされる第4級アンモニウ
ム塩が0.025〜0.05重量%(重量%は、組成物
重量基準。 以下間シ)、コレステロールが0.1〜2,0重量%、
下記一般式(2) %式%(2) (上記式中で、Rは炭素数11〜18のアルキル基また
はアルケニル基、Aはナトリウム、カリウムまたはNH
4である) で表わされる高級アルコール硫酸エステル塩が0.1〜
2重量%、直鎖構造の脂肪酸エステル油が1〜20重量
%、食塩が0.05〜0.5重量%及び水が75〜98
重量%配合されていることを特徴とする、スキン乳液の
組成物。[Scope of Claims] 1 The following general formula (1) (In the above formula, R is an alkyl group or alkenyl group having 6 to 17 carbon atoms, R' is a benzyl group, 4-nitrobenzyl group, 3,4- ) chlorobenzyl group, 4-chlorobenzyl group, 2,4-dichlorobenzyl group, methylbenzyl group or methyl group) quaternary ammonium salt represented by , based on the weight of the composition. Cholesterol: 0.1 to 2.0% by weight,
The following general formula (2) % formula % (2) (In the above formula, R is an alkyl group or alkenyl group having 11 to 18 carbon atoms, A is sodium, potassium or NH
The higher alcohol sulfate ester salt represented by 4) is 0.1 to
2% by weight, linear fatty acid ester oil 1-20% by weight, salt 0.05-0.5% by weight, and water 75-98% by weight.
A skin emulsion composition characterized in that the composition contains % by weight.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3732577A JPS5935363B2 (en) | 1977-03-31 | 1977-03-31 | Composition of skin emulsion |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3732577A JPS5935363B2 (en) | 1977-03-31 | 1977-03-31 | Composition of skin emulsion |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS53127838A JPS53127838A (en) | 1978-11-08 |
| JPS5935363B2 true JPS5935363B2 (en) | 1984-08-28 |
Family
ID=12494489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP3732577A Expired JPS5935363B2 (en) | 1977-03-31 | 1977-03-31 | Composition of skin emulsion |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5935363B2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001516340A (en) * | 1996-12-31 | 2001-09-25 | アメリカン、メディカル、リサーチ、インコーポレーテッド | Antimicrobial, antiviral, antiseptic and healing skin products |
| WO2000000186A1 (en) | 1998-06-30 | 2000-01-06 | American Medical Research, Inc. | Method of treating topical ailments |
-
1977
- 1977-03-31 JP JP3732577A patent/JPS5935363B2/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| JPS53127838A (en) | 1978-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5213792A (en) | Storage-stable pearlescent hair-conditioning compositions | |
| US5759558A (en) | Skin care composition | |
| JP2740148B2 (en) | Cosmetic or dermatological compositions containing a mixture of ceramides and their use for moisturizing the skin | |
| EP0534286B1 (en) | External skin care preparation | |
| DD295310A5 (en) | HAIR CONDITIONING SHAMPOO AND USE THEREOF | |
| DE69700333T2 (en) | Use of oxazolidinone derivatives as penetration-preventing agents in a cosmetic and / or dermatological composition | |
| JPH08283145A (en) | Low-pH external preparation composition for skin | |
| JPS61260008A (en) | Cosmetic composition | |
| US6017548A (en) | Skin care composition | |
| JP3208237B2 (en) | Hair cosmetics | |
| JPS5935363B2 (en) | Composition of skin emulsion | |
| JPS60116618A (en) | Cosmetic | |
| JPH08183726A (en) | Skin preparation for external use | |
| JPS6026086B2 (en) | cosmetics | |
| JPS5935364B2 (en) | Composition of skin emulsion | |
| JPS5914518B2 (en) | Liquid shampoo composition | |
| KR102771094B1 (en) | W/S Type Cosmetic Composition Containing High-Content Potassium Lactate and Silicon Oil | |
| DE1617705C3 (en) | Cosmetic product for hair treatment | |
| JPS5935362B2 (en) | Composition of skin emulsion | |
| JP2003055129A (en) | Emulsified cosmetic | |
| JPH10167948A (en) | Cosmetic | |
| JPH06345620A (en) | Hair cosmetic | |
| JPH09110649A (en) | Composition for hair | |
| JP2835892B2 (en) | Hair cosmetics | |
| JPH0565485B2 (en) |